- The European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) adopts a positive opinion recommending approval for Novartis (NVS +0.1%) unit Sandoz GmbH's Zessly, a biosimilar of Johnson & Johnson's (JNJ -0.1%) Remicade (infliximab).
- A final decision from the European Commission usually takes ~60 days.